Vividion Therapeutics Raises $50M

San Diego-based Vividion Therapeutics, a biopharmaceuticals firm tapping into technology developed at The Scripps Research Insitute, has raised $50M in a Series A funding round. The funding was led by ARCH Venture Partners and Versant Ventures, and also included Cardinal Partners. The company says it has developed a novel drug discovery platform that applies chemical proteomics to treat major unmet clinical needs. The company's technology was spun out of the lab of Ben Cravatt, Professor at The Scripps Research Institute in La Jolla, according to its investors.